Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biohaven Ltd. Common Shares (NY:BHVN)

13.93 -0.14 (-1.00%)
Official Closing Price Updated: 7:00 PM EDT, Sep 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Biohaven Ltd. Common Shares

< Previous 1 2 3 4 5 6 7 8 Next >
IPO Scorcher Amylyx Wins FDA Approval In ALS Treatment, Ending A Long Battle
The drug has faced two advisory committees and a delayed review date. 
Via Investor's Business Daily
Biohaven's ALS Drug Fails To Meet Study Endpoint, Second Therapy To Fail Trials In Recent Months
Biohaven Pharmaceutical Holding Company Ltd (NASDAQ: BHVN) announced results from a focused analysis of verdiperstat in the HEALEY ALS Platform Trial in amyotrophic lateral sclerosis (ALS).  
Via Benzinga
Top-Notch Biohaven Pharmaceutical Stock Trips As ALS Drug Flops In Key Test
Patients didn't show any improvements in a study meant to test multiple drugs. 
Via Investor's Business Daily
Stocks That Hit 52-Week Highs On Friday
  On Friday, 5 companies hit new 52-week highs. 
Via Benzinga
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why. 
Via Investor's Business Daily
Recap: Biohaven Pharma Hldgs Q2 Earnings
Biohaven Pharma Hldgs (NYSE:BHVN) reported its Q2 earnings results on Friday, August 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Biohaven's Neurological Disease Candidate Flunks In Late-Stage Study
 
Via Benzinga
Biohaven Pharmaceutical's Return On Capital Employed Overview
Benzinga Pro data, Biohaven Pharmaceutical (NYSE:BHVN) reported Q2 sales of $215.08 million. Earnings fell to a loss of $441.88 million, resulting in a 278.01% decrease from last quarter. 
Via Benzinga
$5.6 Million Bet On This Healthcare Stock? 3 Stocks Insiders Are Buying
Although US stocks closed sharply lower on Monday, there were a few notable insider trades. 
Via Benzinga
Freedom Biosciences Gets $10.5M In Seed Financing For Psychedelics Research, This Is What We Know
Freedom Biosciences achieved a major $10.5 million in a seed financing round in which MBX Capital, PsyMed Ventures, Village Global and The Yale Startup, among others, participated. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 19, 2022
Upgrades 
Via Benzinga
Why These Pfizer Analysts Like The Global Blood Therapeutics Deal
Pfizer Inc. (NYSE: PFE) shares were trading lower Monday after the drugmaker announced a $5.4-billion bid to acquire blood disorder drugmaker Global Blood Therapeutics Inc (NASDAQ: GBT). 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022
  
Via Benzinga
Pfizer Is Reportedly In 'Advanced Talks' To Buy Global Blood Therapeutics For $5 Billion
Shares of Pfizer's rumored takeover target have rocketed for two days running. 
Via Investor's Business Daily
The 3 Best Market Sectors for the Second Half of 2022
Compelling themes will drive a recovery in some sectors over the second half of 2022. The following are the best market sectors to buy into. 
Via InvestorPlace
Which Coronavirus Stock Could Fetch Higher Returns?
This article will compare Pfizer, Moderna, and Novavax to see which of these coronavirus stocks will yield the highest returns. 
Via InvestorPlace
Is Pfizer Stock A Buy Or A Sell As Its Covid Vaccine Faces A New Lawsuit?
The FDA's advisors recently backed Pfizer's Covid shot for young children. 
Via Investor's Business Daily
Hopeful Golden Cross Forms On Biohaven Pharma Hldgs's Chart
If history is any guide, there may be good fortune ahead for shares of Biohaven Pharma Hldgs (NYSE:BHVN). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish... 
Via Benzinga
Looking Into Biohaven Pharmaceutical's Return On Capital Employed
According to data from Benzinga Pro, during Q1, Biohaven Pharmaceutical's (NYSE:BHVN) reported sales totaled $318.85 million. Despite a 41.43% increase in earnings, the company posted a loss of $116.90... 
Via Benzinga
3 Biotech Stocks to Buy Before They Boom
It could be a “never-before, never-after opportunity” to buy into these biotech stocks that trade at very attractive valuations. 
Via InvestorPlace
Pfizer's Nearly $7 Billion Acquisition Of Arena Pharma Just Paid Off In A Big Way
The company is planning to soon ask for FDA approval of etrasimod in ulcerative colitis. 
Via Investor's Business Daily
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from... 
Via Benzinga
Stock Market Tries To Bounce From Fresh 2022 Lows; Tesla CEO Elon Musk Puts Twitter Deal 'On Hold': Weekly Review
Elon Musk put his Twitter deal "on hold" but says he's "still committed" to it. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2022
Upgrades 
Via Benzinga
103 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Why Is Biohaven Pharmaceutical (BHVN) Stock Up Today?
BHVN stock is enjoying a nearly 70% jump today after Biohaven Pharmaceutical announced it has been acquired by Pfizer. 
Via InvestorPlace
Mid-Afternoon Market Update: Nasdaq Jumps Over 200 Points; Crude Oil Down 3%
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 200 points on Tuesday. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Dow Reverses Morning Rally as Recession Fears Swirl
Stocks are shedding their premarket gains at midday, and are now looking to extend yesterday's major selloff. 
Via Talk Markets
Mid-Day Market Update: U.S. Stocks Turn Lower; Biohaven Pharmaceutical Shares Jump
U.S. stocks turned mostly lower midway through trading, with the Dow Jones dropping more than 100 points on Tuesday. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.